Candel Therapeutics(CADL) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights • On track for topline disease-free survival data from the phase 3 randomized controlled clinical trial of CAN-2409 in localized intermediate/high risk prostate cancer, expected in Q4 2024 • On track for topline progression-free survival data from the phase 2b randomized controlled clinical trial of CAN-2409 in the active surveillance population with localized low/intermediate risk prostate cancer, ...